indapamide has been researched along with Metabolic Syndrome in 10 studies
Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.
indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate effects of 6-month therapy with losartan in combination with indapamide on a clinical course, immunological, metabolic parameters, left ventricular function, exercise tolerance and quality of life in patients with coronary heart disease (CHD) associated with metabolic syndrome (MS)." | 9.14 | [Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus]. ( Bolotskaia, LA; Derbeneva, NV; Frants, MV; Kuznetsova, AV; Lukinov, AV; Maianskaia, SD; Shilov, SN; Stepacheva, TA; Tepliakov, AT; Vdovina, TV, 2009) |
| "The aim of the observational pharmaco-epidemiological study Optimax II was to seek whether the pre-existence of a metabolic syndrome (MS) defined by the NCEP-ATP III criteria impacts blood pressure (BP) control in hypertensive patients receiving a fixed perindopril/indapamide combination therapy." | 9.13 | Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study. ( Guillausseau, PJ; Lameira, D; Mourad, JJ, 2008) |
| "To assess real-life effectiveness of a perindopril/indapamide (Per/Ind) single-pill combination (SPC) in patients with hypertension (HT) and type 2 diabetes mellitus (T2DM), obesity and/or metabolic syndrome (MetS)." | 9.12 | Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies. ( Brzozowska-Villatte, R; De Champvallins, M; Dézsi, CA; Farsang, C; Glezer, M; Karpov, Y, 2021) |
| "Therapy with the use of a fixed combination of perindopril and indapamide was prescribed to 22 patients with metabolic syndrome and I - II degree hypertension for 16 weeks." | 9.12 | [Effect of a fixed combination of perindopril and indapamide on 24-hour blood pressure profile, morpho-functional parameters of the heart, heart rate variability, functional state of the kidney, and quality of life in patients with arterial hypertension c ( Statsenko, ME; Zemlianskaia, MM, 2007) |
| "To study ways of realization of pleiotropic effects of treatment with low-dose combination of perindopril arginine with indapamide in hypertensive patients with metabolic syndrome (MS)." | 7.77 | [Low-dose combination of perindopril arginine with indapamide in correction of metabolic syndrome]. ( , 2011) |
| "To evaluate effects of 6-month therapy with losartan in combination with indapamide on a clinical course, immunological, metabolic parameters, left ventricular function, exercise tolerance and quality of life in patients with coronary heart disease (CHD) associated with metabolic syndrome (MS)." | 5.14 | [Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus]. ( Bolotskaia, LA; Derbeneva, NV; Frants, MV; Kuznetsova, AV; Lukinov, AV; Maianskaia, SD; Shilov, SN; Stepacheva, TA; Tepliakov, AT; Vdovina, TV, 2009) |
| "The aim of the observational pharmaco-epidemiological study Optimax II was to seek whether the pre-existence of a metabolic syndrome (MS) defined by the NCEP-ATP III criteria impacts blood pressure (BP) control in hypertensive patients receiving a fixed perindopril/indapamide combination therapy." | 5.13 | Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study. ( Guillausseau, PJ; Lameira, D; Mourad, JJ, 2008) |
| "To assess real-life effectiveness of a perindopril/indapamide (Per/Ind) single-pill combination (SPC) in patients with hypertension (HT) and type 2 diabetes mellitus (T2DM), obesity and/or metabolic syndrome (MetS)." | 5.12 | Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies. ( Brzozowska-Villatte, R; De Champvallins, M; Dézsi, CA; Farsang, C; Glezer, M; Karpov, Y, 2021) |
| "Therapy with the use of a fixed combination of perindopril and indapamide was prescribed to 22 patients with metabolic syndrome and I - II degree hypertension for 16 weeks." | 5.12 | [Effect of a fixed combination of perindopril and indapamide on 24-hour blood pressure profile, morpho-functional parameters of the heart, heart rate variability, functional state of the kidney, and quality of life in patients with arterial hypertension c ( Statsenko, ME; Zemlianskaia, MM, 2007) |
| "To study ways of realization of pleiotropic effects of treatment with low-dose combination of perindopril arginine with indapamide in hypertensive patients with metabolic syndrome (MS)." | 3.77 | [Low-dose combination of perindopril arginine with indapamide in correction of metabolic syndrome]. ( , 2011) |
| "Seventy five patients with metabolic syndrome aged 40-59 years were included into an open study with parallel groups in which the following combinations of lipid lowering and antihypertensive drugs were used for sweeksinch: atorvastatin + perindopril (n=17, group 1); simvastatin + atenolol (n=17, group 2); fenofibrate + atenolol (n=21, group 3), and simvastatin + indapamide (n=20, group 4)." | 3.72 | [Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome]. ( Khadipash, LA; Kiseleva, NV; Kosmatova, OV; Mamedov, MN; Oganov, RG; Perova, NV, 2003) |
| "Determination of the effectiveness and safety of different dosing regimens during the day (in the morning or at bedtime) combination therapy including azilsartan medoxomil in patients with essential hypertension and metabolic syndrome (MS)." | 1.43 | [Hronotherapy Aspects of Efficiency Azilsartan Medoxomil in Combination Therapy in Patients With Hypertension and Metabolic Syndrome]. ( Fendrikova, AV; Sirotenko, DV; Skibitskiy, AV; Skibitskiy, VV, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farsang, C | 1 |
| Dézsi, CA | 1 |
| Brzozowska-Villatte, R | 1 |
| De Champvallins, M | 1 |
| Glezer, M | 1 |
| Karpov, Y | 1 |
| Skibitskiy, VV | 1 |
| Fendrikova, AV | 1 |
| Sirotenko, DV | 1 |
| Skibitskiy, AV | 1 |
| Mourad, JJ | 1 |
| Lameira, D | 1 |
| Guillausseau, PJ | 1 |
| Tepliakov, AT | 1 |
| Maianskaia, SD | 1 |
| Bolotskaia, LA | 1 |
| Vdovina, TV | 1 |
| Stepacheva, TA | 1 |
| Kuznetsova, AV | 1 |
| Lukinov, AV | 1 |
| Derbeneva, NV | 1 |
| Frants, MV | 1 |
| Shilov, SN | 1 |
| Efimova, IIu | 1 |
| Kalashnikova, TP | 1 |
| Lishmanov, IuB | 1 |
| Mamedov, MN | 1 |
| Perova, NV | 1 |
| Kosmatova, OV | 1 |
| Khadipash, LA | 1 |
| Kiseleva, NV | 1 |
| Oganov, RG | 1 |
| Trusov, VV | 1 |
| Filimonov, MA | 1 |
| Aksenov, KV | 1 |
| Sergienko, VB | 1 |
| Gornostaev, VV | 1 |
| Bugriĭ, ME | 1 |
| Mychka, VB | 1 |
| Chazova, IE | 1 |
| Statsenko, ME | 1 |
| Zemlianskaia, MM | 1 |
1 review available for indapamide and Metabolic Syndrome
| Article | Year |
|---|---|
Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combinations; Humans; | 2021 |
5 trials available for indapamide and Metabolic Syndrome
| Article | Year |
|---|---|
Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diuretics; | 2008 |
[Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiotonic Agents; C | 2009 |
[The impact of antihypertensive therapy on cerebral hemodynamics in patients with metabolic syndrome].
Topics: Antihypertensive Agents; Biological Availability; Blood Pressure Monitoring, Ambulatory; Brain; Cere | 2012 |
[Correction of endothelial dysfunction by noliprel in patients with metabolic syndrome].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Combinations; Endothel | 2005 |
[Effect of a fixed combination of perindopril and indapamide on 24-hour blood pressure profile, morpho-functional parameters of the heart, heart rate variability, functional state of the kidney, and quality of life in patients with arterial hypertension c
Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hypertensi | 2007 |
4 other studies available for indapamide and Metabolic Syndrome
| Article | Year |
|---|---|
[Hronotherapy Aspects of Efficiency Azilsartan Medoxomil in Combination Therapy in Patients With Hypertension and Metabolic Syndrome].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arterial Pressure; Benzimida | 2016 |
[Low-dose combination of perindopril arginine with indapamide in correction of metabolic syndrome].
Topics: Antihypertensive Agents; Comorbidity; Drug Administration Schedule; Drug Therapy, Combination; Femal | 2011 |
[Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome].
Topics: Adult; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholestero | 2003 |
[Cerebral and myocardial perfusion in patients with arterial hypertension and metabolic syndrome after monotherapy with combined drug noliprel].
Topics: Angiotensin-Converting Enzyme Inhibitors; Brain; Cerebrovascular Circulation; Coronary Circulation; | 2006 |